PLx Pharma Winddown Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

PLx Pharma Winddown şirketinin toplam hissedar öz sermayesi $26.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $33.2M ve $6.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$25.83m
Eşitlik	US$26.33m
Toplam yükümlülükler	US$6.89m
Toplam varlıklar	US$33.22m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1D5A 'nin kısa vadeli varlıkları ( $30.2M ) kısa vadeli yükümlülüklerini ( $6.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1D5A şirketinin kısa vadeli varlıkları ( $30.2M ) uzun vadeli yükümlülüklerini ( $582.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1D5A borçsuzdur.

Borcun Azaltılması: 1D5A şirketinin 5 yıl önce borç/öz sermaye oranı 56.2% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 1D5A şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: 1D5A tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

PLx Pharma Winddown Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

PLx Pharma Winddown Corp. Files Form 15

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Recent updates

PLx Pharma Winddown Corp. Files Form 15

Plx Pharma Winddown Corp. Announces Executive Changes

Insufficient new directors

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022

PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022

Key Executive recently bought €46k worth of stock

Key Executive recently bought €46k worth of stock

No longer forecast to breakeven

PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022

PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month

PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August

Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August

Executive Chairman recently bought €82k worth of stock

Revenue in line with expectations

Executive Chairman recently bought €168k worth of stock

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.

PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 Mg

New 90-day high: €6.05

New 90-day high: €5.20

PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration

PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

New 90-day high: €3.58

Revenue in line with expectations

PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020

PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020

PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin